β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia.
- Publisher:
- WILEY
- Publication Type:
- Journal Article
- Citation:
- J Am Heart Assoc, 2016, 5, (2), pp. e002824
- Issue Date:
- 2016-02-19
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Karimi Galougahi, K | |
dc.contributor.author | Liu, C-C | |
dc.contributor.author |
Garcia, A |
|
dc.contributor.author |
Gentile, C |
|
dc.contributor.author | Fry, NA | |
dc.contributor.author | Hamilton, EJ | |
dc.contributor.author | Hawkins, CL | |
dc.contributor.author | Figtree, GA | |
dc.date.accessioned | 2022-08-08T09:49:05Z | |
dc.date.available | 2022-08-08T09:49:05Z | |
dc.date.issued | 2016-02-19 | |
dc.identifier.citation | J Am Heart Assoc, 2016, 5, (2), pp. e002824 | |
dc.identifier.issn | 2047-9980 | |
dc.identifier.issn | 2047-9980 | |
dc.identifier.uri | http://hdl.handle.net/10453/159767 | |
dc.description.abstract | BACKGROUND: Perturbed balance between NO and O2 (•-). (ie, NO/redox imbalance) is central in the pathobiology of diabetes-induced vascular dysfunction. We examined whether stimulation of β3 adrenergic receptors (β3 ARs), coupled to endothelial nitric oxide synthase (eNOS) activation, would re-establish NO/redox balance, relieve oxidative inhibition of the membrane proteins eNOS and Na(+)-K(+) (NK) pump, and improve vascular function in a new animal model of hyperglycemia. METHODS AND RESULTS: We established hyperglycemia in male White New Zealand rabbits by infusion of S961, a competitive high-affinity peptide inhibitor of the insulin receptor. Hyperglycemia impaired endothelium-dependent vasorelaxation by "uncoupling" of eNOS via glutathionylation (eNOS-GSS) that was dependent on NADPH oxidase activity. Accordingly, NO levels were lower while O2 (•-) levels were higher in hyperglycemic rabbits. Infusion of the β3 AR agonist CL316243 (CL) decreased eNOS-GSS, reduced O2 (•-), restored NO levels, and improved endothelium-dependent relaxation. CL decreased hyperglycemia-induced NADPH oxidase activation as suggested by co-immunoprecipitation experiments, and it increased eNOS co-immunoprecipitation with glutaredoxin-1, which may reflect promotion of eNOS de-glutathionylation by CL. Moreover, CL reversed hyperglycemia-induced glutathionylation of the β1 NK pump subunit that causes NK pump inhibition, and improved K(+)-induced vasorelaxation that reflects enhancement in NK pump activity. Lastly, eNOS-GSS was higher in vessels of diabetic patients and was reduced by CL, suggesting potential significance of the experimental findings in human diabetes. CONCLUSIONS: β3 AR activation restored NO/redox balance and improved endothelial function in hyperglycemia. β3 AR agonists may confer protection against diabetes-induced vascular dysfunction. | |
dc.format | Electronic | |
dc.language | eng | |
dc.publisher | WILEY | |
dc.relation.ispartof | J Am Heart Assoc | |
dc.relation.isbasedon | 10.1161/JAHA.115.002824 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 1102 Cardiorespiratory Medicine and Haematology | |
dc.subject.mesh | Adrenergic beta-3 Receptor Agonists | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Blood Glucose | |
dc.subject.mesh | Diabetes Mellitus, Experimental | |
dc.subject.mesh | Diabetic Angiopathies | |
dc.subject.mesh | Dioxoles | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Endothelium, Vascular | |
dc.subject.mesh | Enzyme Activation | |
dc.subject.mesh | Glutathione | |
dc.subject.mesh | Hyperglycemia | |
dc.subject.mesh | Hypoglycemic Agents | |
dc.subject.mesh | Male | |
dc.subject.mesh | NADPH Oxidases | |
dc.subject.mesh | Nitric Oxide | |
dc.subject.mesh | Nitric Oxide Synthase Type III | |
dc.subject.mesh | Oxidation-Reduction | |
dc.subject.mesh | Oxidative Stress | |
dc.subject.mesh | Peptides | |
dc.subject.mesh | Rabbits | |
dc.subject.mesh | Receptors, Adrenergic, beta-3 | |
dc.subject.mesh | Signal Transduction | |
dc.subject.mesh | Sodium-Potassium-Exchanging ATPase | |
dc.subject.mesh | Superoxides | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Endothelium, Vascular | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Rabbits | |
dc.subject.mesh | Diabetic Angiopathies | |
dc.subject.mesh | Diabetes Mellitus, Experimental | |
dc.subject.mesh | Hyperglycemia | |
dc.subject.mesh | Superoxides | |
dc.subject.mesh | Nitric Oxide | |
dc.subject.mesh | Dioxoles | |
dc.subject.mesh | Blood Glucose | |
dc.subject.mesh | Peptides | |
dc.subject.mesh | Glutathione | |
dc.subject.mesh | Receptors, Adrenergic, beta-3 | |
dc.subject.mesh | Hypoglycemic Agents | |
dc.subject.mesh | Signal Transduction | |
dc.subject.mesh | Enzyme Activation | |
dc.subject.mesh | Oxidation-Reduction | |
dc.subject.mesh | Oxidative Stress | |
dc.subject.mesh | Dose-Response Relationship, Drug | |
dc.subject.mesh | Time Factors | |
dc.subject.mesh | Male | |
dc.subject.mesh | Nitric Oxide Synthase Type III | |
dc.subject.mesh | Sodium-Potassium-Exchanging ATPase | |
dc.subject.mesh | Adrenergic beta-3 Receptor Agonists | |
dc.subject.mesh | NADPH Oxidases | |
dc.title | β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia. | |
dc.type | Journal Article | |
utslib.citation.volume | 5 | |
utslib.location.activity | England | |
utslib.for | 1102 Cardiorespiratory Medicine and Haematology | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Strength - CHT - Health Technologies | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
pubs.organisational-group | /University of Technology Sydney/Centre for Health Technologies (CHT) | |
utslib.copyright.status | open_access | * |
dc.date.updated | 2022-08-08T09:49:04Z | |
pubs.issue | 2 | |
pubs.publication-status | Published online | |
pubs.volume | 5 | |
utslib.citation.issue | 2 |
Abstract:
BACKGROUND: Perturbed balance between NO and O2 (•-). (ie, NO/redox imbalance) is central in the pathobiology of diabetes-induced vascular dysfunction. We examined whether stimulation of β3 adrenergic receptors (β3 ARs), coupled to endothelial nitric oxide synthase (eNOS) activation, would re-establish NO/redox balance, relieve oxidative inhibition of the membrane proteins eNOS and Na(+)-K(+) (NK) pump, and improve vascular function in a new animal model of hyperglycemia. METHODS AND RESULTS: We established hyperglycemia in male White New Zealand rabbits by infusion of S961, a competitive high-affinity peptide inhibitor of the insulin receptor. Hyperglycemia impaired endothelium-dependent vasorelaxation by "uncoupling" of eNOS via glutathionylation (eNOS-GSS) that was dependent on NADPH oxidase activity. Accordingly, NO levels were lower while O2 (•-) levels were higher in hyperglycemic rabbits. Infusion of the β3 AR agonist CL316243 (CL) decreased eNOS-GSS, reduced O2 (•-), restored NO levels, and improved endothelium-dependent relaxation. CL decreased hyperglycemia-induced NADPH oxidase activation as suggested by co-immunoprecipitation experiments, and it increased eNOS co-immunoprecipitation with glutaredoxin-1, which may reflect promotion of eNOS de-glutathionylation by CL. Moreover, CL reversed hyperglycemia-induced glutathionylation of the β1 NK pump subunit that causes NK pump inhibition, and improved K(+)-induced vasorelaxation that reflects enhancement in NK pump activity. Lastly, eNOS-GSS was higher in vessels of diabetic patients and was reduced by CL, suggesting potential significance of the experimental findings in human diabetes. CONCLUSIONS: β3 AR activation restored NO/redox balance and improved endothelial function in hyperglycemia. β3 AR agonists may confer protection against diabetes-induced vascular dysfunction.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph